Growth Hormone or Sildenafil as Therapies for Fatigue in MTBI
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 1
- 主要终点
- Performance fatigue as measured by using hand grip dynamometry at baseline
研究概览
简要总结
The overall goal is to determine whether perceptual or performance fatigue can be reduced in MTBI patients with and without growth hormone (GH) deficiency by treating them in a crossover fashion based upon GH status.
A battery of functional, fatigue, cognitive, imaging and blood flow tests will be performed to assess the efficacy of the two drug interventions, Growth hormone and Sildenafil.
详细描述
Three primary outcome measures are proposed:
- Perceptual fatigue as measured weekly using the Brief Fatigue Inventory (BFI) (59).
- Performance fatigue as measured at baseline and month 3, 6 and 12 using hand and leg dynamometry.
- Neuropsychological function as measured at baseline and month 12.
Secondary outcomes will include:
- Modified 6 minute walk performance as measured at baseline, and month 3, 6 and 12.
- Mood and quality of life using the Profile of Mood States, Quality of Life Assessment of GH Deficiency in Adults questionnaire, and a grief assessment (60) (POMS), measured at baseline, and month 3, 6, and 12.
- Sleep quality using the Pittsburgh Sleep Quality Index (PSQI), baseline, and month 3, 6, and 12.
- Multidimensional fatigue using Multidimensional Fatigue Symptom Inventory (MFSI) at baseline, and month 3, 6 and 12.
- Skeletal muscle mass, as derived from lean body mass determinations, using dual energy X-ray absorptiometry (iDEXA) at baseline, and month 3, 6, and 12.
- Physical Activity, measured daily using accelerometry.
- Cerebral blood oxygen saturation measured at baseline and month 12.
- Leg blood flow measured at baseline, and month 3, 6 and 12.
- Blood Hormones at baseline and month 3, 6 and 12.
- Characterization of brain tissue using structural, "resting state" and diffusion functional MR at baseline and month 3, 6, and 12.
- Indirect calorimetry measured at baseline and month 3, 6 and 12.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Diagnostic
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female with a diagnosis of mild TBI and 6 month post-injury. Age 18 to 60 years. Complaint of fatigue, with score of 3 or greater on questions 1, 2, or 3 of the Brief Fatigue Inventory.
排除标准
- •Exclusion criteria (general)
- •Significant heart, liver, kidney, blood or respiratory disease.
- •Active coronary disease.
- •Alcohol or drug abuse.
- •Unable to walk unassisted.
- •Diabetes mellitus and anterior pituitary abnormalities diagnosed upon screening.
- •Premorbid history of psychiatric disorder.
- •Premorbid history of head trauma.
- •Exclusion criteria (sildenafil/placebo group)
- •Use of nitrates.
- •Use of alpha blockers.
- •Systolic blood pressure <100 or >150, diastolic blood pressure <60 or >
- •This range is smaller than the acceptable range stated in the prescribing information for sildenafil (>90/50 and <170/110).
- •Peripheral vascular disease.
- •Use of a phosphodiesterase 5 inhibitor.
- •Exclusion criteria (growth hormone/placebo group)
- •Coumadin because of the risk of bleeding with daily injections of Recombinant Human Growth Hormone (rhGH) in the growth hormone (GH) arm of the study.
- •Subjects who are deficient in cortisol or thyroid at screening will be excluded until hormone abnormalities have been corrected.
- •Subjects with chronic pain who are being managed with narcotics will be excluded as the effects of central nervous system depressants may interfere with study test results.
研究组 & 干预措施
Recombinant Growth Hormone
Double blind placebo/Genotropin cross over design for 6 months with cross over at 3 months. Then open label Genotropin from month 6 - 12.
干预措施: Growth Hormone (Drug)
Recombinant Growth Hormone
Double blind placebo/Genotropin cross over design for 6 months with cross over at 3 months. Then open label Genotropin from month 6 - 12.
干预措施: Placebo (Drug)
Sildenafil
Double blinded placebo/Sildenafil crossover design for 6 months with crossover at month 3. Then open label Sildenafil from months 6-12.
干预措施: Sildenafil (Drug)
Sildenafil
Double blinded placebo/Sildenafil crossover design for 6 months with crossover at month 3. Then open label Sildenafil from months 6-12.
干预措施: Placebo (Drug)
结局指标
主要结局
Performance fatigue as measured by using hand grip dynamometry at baseline
时间窗: baseline
Hand grip exercises will be used to measure performance fatigue at baseline
Performance fatigue as measured by using hand grip dynamometry at 3 months
时间窗: 3 months
Hand grip exercises will be used to measure performance fatigue after 3 months of study intervention
Performance fatigue as measured by using hand grip dynamometry at 12 months
时间窗: 12 months
Hand grip exercises will be used to measure performance fatigue after 12 months of study intervention
Performance fatigue as measured by using hand grip dynamometry at 6 months
时间窗: 6 months
Hand grip exercises will be used to measure performance fatigue after 6 months of study intervention
Performance fatigue as measured by using leg dynamometry at baseline
时间窗: baseline
Leg exercises will be used to measure performance fatigue at baseline
Performance fatigue as measured by using leg dynamometry at 12 months
时间窗: 12 months
Leg exercises will be used to measure performance fatigue after 12 months of study
Performance fatigue as measured by using leg dynamometry at 3 months
时间窗: 3 months
Leg exercises will be used to measure performance fatigue after 3 months of study intervention.
Performance fatigue as measured by using leg dynamometry at 6 months
时间窗: 6 months
Leg exercises will be used to measure performance fatigue after 6 months of study intervention.
次要结局
未报告次要终点